Business Wire

ASICS Study Shows Exercise Has the Power to Sharpen Even the Brightest Minds and Improve Mental Performance

20.1.2023 12:23:00 EET | Business Wire | Press release

Share

Today, ASICS reveals exercise can significantly improve cognitive function and advance mental performance.​ From boosting short-term memory to increasing concentration levels, exercise enhances brain power and could be the solution to helping us pass exams or excel at work.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230119005693/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Memory sport competitor, Ben Pridmore took part in the ASICS Mind Games study (Photo: Business Wire)

In a unique experiment, ASICS invited competitive gamers from around the world, specialising in mind games such as Chess and Esports and who rely on their cognitive function, to start an exercise programme. After four months of regular exercise, their minds were significantly sharpened and they performed at an even higher competitive level.

Participants’ international gaming rankings improved by an incredible 75% proving, yet again, the close interplay between our mind and body. The mind gamers’ cognitive function was boosted on average by 10%, with problem solving abilities improving by 9%, short-term memory increasing by 12% and processing speed and alertness improving by 10%. Group confidence levels increased by 44%, concentration improved by 33% and anxiety levels plummeted by 43%. The research shows exercise can be as effective at boosting brain function as learning a second language, daily reading, playing a new musical instrument or completing a puzzle every day.i

Professor Brendon Stubbs, a renowned researcher in movement and the mind, developed and led the experiment. Each gamer followed a training programme designed by runner turned international coach, Andrew Kastor. The programme included medium impact cardio and strength training and increased the gamers exercise levels to 150 minutes a week. Professor Stubbs measured the mental improvement of the participants based on their performance in their mind games, cognitive tests and wellbeing questionnaires over the course of their four-month research period.

Commenting on the results, Professor Brendon Stubbs said: “We all know that exercise is good for our mental and physical health but the impact on cognitive functioning has been less explored. We wanted to examine the effects of exercise on people who depend on their cognitive abilities - competitive mind gamers. Our results show significant improvements in their cognitive functioning, including concentration levels and problem-solving abilities.

“Exercise stimulates cell growth in the brain and rapidly increases blood flow to the hippocampus and prefrontal cortex, mechanisms that enable us to better retain memories, process information and problem solve quickly. If exercise can significantly increase the mental performance of professional mind gamers, imagine what it could do for the rest of us. From increasing focus when revising for an exam or improving alertness before a work presentation, exercise truly can enhance brain power.”

As well as showing that exercise improved the participants cognitive function and gaming capabilities, Professor Stubbs also found that the gamers’ mental wellbeing was significantly uplifted, with average State of Mind scores improving by 31%.ii The gamers’ average state of mind score at the start of the study was a below average 58 and at the end it was a high 76iii, demonstrating the significant impact exercise can also have on your mental wellbeing.

The study’s Head Coach, Andrew Kastor, who developed the gamers’ training programmes, stated: “These results are astonishing and speak to the power of exercise. Many of the gamers couldn’t jog for longer than a minute at the start of the study, so their training programmes had to be moderate. 150 minutes a week sounds a lot but when you break it down this could be 5 sets of 30 minutes. No matter your fitness levels, the mental benefits of exercise are accessible to all.”

Inspired by the experiment, a camera crew followed four competitive gamers as they took on regular exercise to improve their rankings on the international stage. The result was a new ground-breaking documentary ‘Mind Games – The Experiment’, narrated by the internationally acclaimed actor, and mental health campaigner, Stephen Fry. Now available to stream on Prime Video, the feature length film documents the journeys of four gamers – Kassa Korley, Ryoei Hirano, Ben Pridmore and Sherry Nhan – who specialise in Chess, Mahjong, Memory and Esports as they compete in professional tournaments around the world. Watch the documentary trailer here.

Gary Raucher, EVP, ASICS EMEA said: “Our founding philosophy is literally in our name, Anima Sana In Corpore Sano or a Sound Mind in a Sound Body. We have always encouraged utilising exercise for both physical and mental benefits, but this is the first time we have explored the true impact on cognitive functioning. Mind Games – The Experiment shows the power of exercise to sharpen the mind and we hope that after watching the documentary, everyone (regardless of their age, body type or fitness level) is inspired to move to help boost their brain.”

Mind Games - The Experiment is available to stream on Prime Video from 19th January 2023.

ENDS

Notes to Editors

The ASICS study ran from May – September 2022, with 77 gamers from 20 countries completing the experiment. All passed health screening questionnaires and completed consent forms before taking part.

For further information, images or to organise an interview with Professor Brendon Stubbs, Head Coach Andrew Kastor, or one of the gamers featured in the documentary, please contact Rory Cramsie at ASICSMindGames@golin.com

i Comparisons drawn from: https://journals.sagepub.com/doi/full/10.1177/09567976221092726 and https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174231/ and https://www.frontiersin.org/articles/10.3389/fnagi.2021.706672/full#:~:text=Bilingualism%20has%20been%20linked%20to,cognitive%20enhancement%20in%20older%20adults

ii ASICS proprietary State of Mind score is a rating out of 100 made up of 10 emotional and cognitive metrics, including: composure, resilience, positivity, contentment, relaxation, confidence, alertness, calmness, focus and energy.

iii After four months the groups state of mind score increased into the top 10% globally.

Anima Sana In Corpore Sano, meaning “A Sound Mind in a Sound Body,” is an old Latin phrase from which ASICS is derived and the fundamental platform on which the brand still stands. The company was founded in 1949 by Kihachiro Onitsuka and is now a leading designer, developer and manufacturer of running shoes, as well as various sports footwear, apparel and accessories. For more information, visit www.asics.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Rory Cramsie
ASICSMindGames@golin.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release

Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ

Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release

Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli

HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release

HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev

SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release

Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin

Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye